The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Stephanie Link, TIAA Global Asset Management Portfolio Manager, went looking for value in the Healthcare sector on today's Halftime Report.
Link thinks investors should be watching Abbott Labs.
Although she says Abbott Labs has "substantially lagged" in the med-tech sector, she still believes the stock is a buy. Stephanie argues the stock trades at a rare discount to its peers and has large emerging market exposure.
One thing that has been weighing on the stock is its recent deal with St. Jude Medical, but Link thinks this deal will be good for the company in the long term.
"I think once it closes, which is in the 4th quarter of this year, you're going to see good synergy; something to the tune of like 5 to 6% sustainable total top line revenue growth and 10 to 11% bottom line growth , that's going to be better than their peers, " said Link.
Link is long Abbott Labs.
Trader disclosure: Stephanie Link owns Abbott Laboratories.